WPD Pharmaceuticals Licensor Granted Another Key Patent for the Development of WPD101 Drug Candidate
28 mai 2020 07h30 HE
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, May 28, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”), a clinical stage pharmaceutical company, is pleased to...
WPD Pharmaceuticals To Resume Trading
15 mai 2020 12h24 HE
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, May 15, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical stage pharmaceutical company, announces that its...
WPD Pharmaceuticals Comments on SEC Order
05 mai 2020 16h01 HE
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, May 05, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical stage pharmaceutical company, clarifies the...
WPD Pharmaceuticals and CNS Pharmaceuticals Identify Leading Polish Medical Institutions for Berubicin Phase 2 Clinical Trial
30 avr. 2020 08h00 HE
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, April 30, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO) (FSE: 8SV1) (the “Company” or “WPD”) a clinical stage pharmaceutical company, is pleased to...
WPD Pharmaceutical’s Annamycin Drug Approved for Accelerated European Clinical Trial
29 avr. 2020 03h05 HE
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, April 29, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO) (FSE: 8SV1) (the “Company” or “WPD”) a clinical stage pharmaceutical company is pleased to...
WPD Pharmaceuticals Announces FDA Application Under The Orphan Drug Act Was Submitted By License Partner for Brain Cancer Drug, Berubicin
24 avr. 2020 03h05 HE
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, April 24, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical stage pharmaceutical company is pleased to...
WPD Pharmaceuticals’ Annamycin Drug Candidate Meets Endpoint in Successful U.S. Phase 1 AML Trial With No Evidence of Cardiotoxicity
23 avr. 2020 03h05 HE
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, April 23, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO) (FSE: 8SV1) (the “Company” or “WPD”) a clinical stage pharmaceutical company is pleased to...
WPD Pharmaceuticals and CNS Pharmaceuticals Announce Additional Coronavirus Testing on WP1122 by ImQuest Biosciences
21 avr. 2020 07h00 HE
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, April 21, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO) (FSE: 8SV1) (the “Company” or “WPD”) a clinical stage pharmaceutical company along with its...
WPD Pharmaceuticals’ License Partner, Moleculin Biotech to Host Conference Call to Discuss COVID-19 Potential in WP1122 Drug Candidate
16 avr. 2020 03h05 HE
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, April 16, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical stage pharmaceutical company announces that its...
WPD Pharmaceuticals to Resume Trading on Monday, April 13, 2020
13 avr. 2020 03h05 HE
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, April 13, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical stage pharmaceutical company reports that the...